EXHIBIT 2.1 TRANSACTION AGREEMENT by and between EXSCIENTIA PLC and RECURSION PHARMACEUTICALS, INC. Dated as of August 8, 2024 TABLE OF CONTENTS Page ARTICLE I THE TRANSACTION 2 Section 1.01 The Transaction 2 Section 1.02 Closing 2 Section 1.03 Delivery of Court Order 2 ARTICLE II TRANSFER OF SCHEME SHARES; DELIVERY OF EXCHANGE SHARES 3 Section 2.01 Transfer of Scheme Shares 3 Section 2.02 Delivery of Exchange Shares 5 Section 2.03 Company Long Term Incentive Awards 6 Section 2.04 Withholding Rights 9 Secti ...

Salt Lake City, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will provide business updates and report its Q2 2024 financial results on Thursday, August 8, 2024, before the opening of the financial markets. Recursion will host a L(earnings) Call on August 8, 2024 at 8:30 am Eastern Time / 6:30 am Mountain Time, interacting with a broad public audience around notable business developments and offering oppo ...

Salt Lake City, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will provide business updates and report its Q2 2024 financial results on Thursday, August 8, 2024, before the opening of the financial markets. Recursion will host a L(earnings) Call on August 8, 2024 at 8:30 am Eastern Time / 6:30 am Mountain Time, interacting with a broad public audience around notable business developments and offering oppo ...

It's likely to experience a lot of growth. As a young and innovative company that heavily emphasizes the "tech" portion of the term "biotech," Recursion Pharmaceuticals (RXRX -3.56%) is a classic contender for being the kind of stock that can turn investors into millionaires. It has flashy technology and pioneering drug development methods. But can those really drive returns on the scale needed to make a relatively small investment grow to be worth millions? Buckle up and get ready for some calculations, be ...

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $8.19, demonstrating a -1.92% swing from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 0.08%. Meanwhile, the Dow experienced a drop of 0.12%, and the technology-dominated Nasdaq saw an increase of 0.07%. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$1.56 per share and revenue of $47.44 million, indicating changes of +1.27% and +6.43%, respectively, compared ...

There's a lot to like about the company using automation and artificial intelligence to improve the new drugdiscovery process. Recursion Pharmaceuticals (RXRX 3.73%) is a start-up biotech company with an important twist. It's using automation technology and artificial intelligence (AI) to industrialize new drug discovery. Why Recursion Pharmaceuticals looks like a good investment New drug candidates discovered by Recursion should also have a better chance at success in clinical trials because there's a lot ...

Amidst the artificial intelligence (AI) revolution and a rapidly shifting landscape in drug development, Recursion Pharmaceuticals (RXRX 8.85%) is aiming to position itself at the intersection of both big trends. While it isn't the only biotech exploring these rising opportunities, it just might be one of the few to have what's needed to succeed in such a dynamic time. The core problem Recursion seeks to solve is that the process of discovering and making new medicines is becoming slower and more costly ove ...

This biotech is on the verge of a groundbreaking innovation, but it might not get over the hump. Reason to buy: A potential paradigm shift That's where Recursion Pharmaceuticals comes in. Its AI algorithm is designed to test various clinical compounds against a library of human genes it contains. It helps predict which compounds are the most likely to be effective at treating various illnesses, thereby speeding up the discovery process and reducing the risk that drugs that enter clinical trials will fail so ...

Goldman Sachs & Co. LLC and J.P. Morgan are acting as lead book-running managers for the offering. Allen & Company LLC is acting as book-running manager for the offering. About Recursion Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the pricing of its underwritten public offering of 30,769,230 shares of its Class A common stock at a pric ...

Goldman Sachs & Co. LLC and J.P. Morgan are acting as lead book-running managers for the offering. Allen & Company LLC is acting as book-running manager for the offering. About Recursion Forward-Looking Statements Investor Contact: media@recursion.com Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the pricing of its underwritten public of ...